Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cortexyme Inc (CRTX)

Cortexyme Inc (CRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,292
  • Shares Outstanding, K 30,151
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,950 K
  • 60-Month Beta 1.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.92
Trade CRTX with:

Options Overview Details

View History
  • Implied Volatility 118.50% ( -4.83%)
  • Historical Volatility 86.31%
  • IV Percentile 62%
  • IV Rank 13.49%
  • IV High 508.91% on 10/15/21
  • IV Low 57.61% on 07/08/21
  • Put/Call Vol Ratio 0.37
  • Today's Volume 41
  • Volume Avg (30-Day) 180
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 21,360
  • Open Int (30-Day) 20,317

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.77
  • Number of Estimates 1
  • High Estimate -0.77
  • Low Estimate -0.77
  • Prior Year -0.74
  • Growth Rate Est. (year over year) -4.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.00 +10.00%
on 05/12/22
4.34 -23.96%
on 04/20/22
-1.02 (-23.61%)
since 04/19/22
3-Month
3.00 +10.00%
on 05/12/22
6.80 -51.47%
on 04/05/22
-1.19 (-26.50%)
since 02/18/22
52-Week
3.00 +10.00%
on 05/12/22
121.98 -97.29%
on 08/10/21
-34.25 (-91.21%)
since 05/19/21

Most Recent Stories

More News
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company...

CRTX : 3.30 (+0.92%)
Cortexyme Announces Agreement to Acquire Novosteo

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement...

CRTX : 3.30 (+0.92%)
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX

WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Cortexyme, Inc. (NASDAQ: CRTX) resulting from allegations...

CRTX : 3.30 (+0.92%)
Notable Tuesday Option Activity: CRTX, XPOF, SPNS

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cortexyme Inc , where a total of 3,250 contracts have traded so far, representing approximately...

CRTX : 3.30 (+0.92%)
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, presented new...

CRTX : 3.30 (+0.92%)
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced...

CRTX : 3.30 (+0.92%)
Cortexyme to Present New GAIN Trial Data at AD/PD 2022

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that...

CRTX : 3.30 (+0.92%)
CORTEXYME ALERT: Bragar Eagel & Squire, P.C. is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cortexyme, Inc. (“Cortexyme” or the “Company”) (NASDAQ: CRTX) on behalf...

CRTX : 3.30 (+0.92%)
CORTEXYME ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cortexyme, Inc. (“Cortexyme” or the “Company”) (NASDAQ: CRTX) on behalf...

CRTX : 3.30 (+0.92%)
Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks

Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising...

CRTX : 3.30 (+0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cortexyme Inc. is a clinical-stage biopharmaceutical company. It is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The company's drug candidate consists of COR388 which is in clinical stage. Cortexyme Inc. is based in San Francisco, United States....

See More

Key Turning Points

3rd Resistance Point 3.73
2nd Resistance Point 3.61
1st Resistance Point 3.46
Last Price 3.30
1st Support Level 3.19
2nd Support Level 3.07
3rd Support Level 2.92

See More

52-Week High 121.98
Fibonacci 61.8% 76.53
Fibonacci 50% 62.49
Fibonacci 38.2% 48.45
Last Price 3.30
52-Week Low 3.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar